“For decades, Boehringer Ingelheim has been committed to improving outcomes for people living with serious respiratory diseases such as interstitial lung diseases and chronic obstructive pulmonary disorder COPD,” said Boehringer Ingelheim's Edward Hollywood.
Boehringer Ingelheim and Heart of Australia take mobile lung care deeper into regional Australia
April 24, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Pharmac announces plan to revise it recently expanded patient advisory function
August 4, 2026 - - Latest News -
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - - Latest News -
This complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News

